Validation of the freezing of gait questionnaire in patients with Parkinson's disease
Identifieur interne : 000231 ( France/Analysis ); précédent : 000230; suivant : 000232Validation of the freezing of gait questionnaire in patients with Parkinson's disease
Auteurs : Nir Giladi [Israël] ; Joseph Tal [Israël] ; Tali Azulay [Israël] ; Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Eldad Melamed [Israël] ; Wolfgang Oertel [Allemagne] ; Werner Poewe [Autriche] ; Fabrizio Stocchi [Italie] ; Eduardo Tolosa [Espagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2009-04-15.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Congélation, Homme.
English descriptors
- KwdEn :
- Aged, Analysis of Variance, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Catechols (therapeutic use), Double-Blind Method, Female, Freezing, Freezing Reaction, Cataleptic (drug effects), Freezing Reaction, Cataleptic (physiology), Gait Disorders, Neurologic (chemically induced), Gait Disorders, Neurologic (diagnosis), Gait Disorders, Neurologic (drug therapy), Gait Disorders, Neurologic (physiopathology), Human, Humans, Indans (therapeutic use), Levodopa (adverse effects), Male, Middle Aged, Nervous system diseases, Neuroprotective Agents (therapeutic use), Nitriles (therapeutic use), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Principal Component Analysis, Psychiatric Status Rating Scales, Questionnaire, Questionnaires, Rasagiline, Reproducibility of Results, Severity of Illness Index, Statistics as Topic, Validation, freezing of gait, rasagiline, validation.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Catechols, Indans, Neuroprotective Agents, Nitriles.
- chemically induced : Gait Disorders, Neurologic.
- diagnosis : Gait Disorders, Neurologic.
- drug effects : Freezing Reaction, Cataleptic.
- drug therapy : Gait Disorders, Neurologic, Parkinson Disease.
- physiology : Freezing Reaction, Cataleptic.
- physiopathology : Gait Disorders, Neurologic.
- Aged, Analysis of Variance, Double-Blind Method, Female, Humans, Male, Middle Aged, Principal Component Analysis, Psychiatric Status Rating Scales, Questionnaires, Reproducibility of Results, Severity of Illness Index, Statistics as Topic.
Abstract
To revalidate the Freezing of Gait Questionnaire (FOG‐Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each dose of levodopa) (n = 150), or placebo (n = 154). Patients were assessed at baseline and after 10 weeks using the FOG‐Q, Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory (BDI), and Parkinson's Disease Questionnaire (PDQ‐39). FOG‐Q dimensionality, test–retest reliability, and internal reliability were examined. Convergent and divergent validities were assessed by correlating FOG‐Q with UPDRS, BDI, and PDQ‐39. Comparisons between FOG‐Q item 3 and UPDRS item 14 were also made. Principal component analysis indicated that FOG‐Q measures a single dimension. Test–retest reliability and internal reliability of FOG‐Q score was high. FOG‐Q was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility. Correlations between baseline and endpoint suggested that FOG‐Q item 3 is at least as reliable as UPDRS item 14. At baseline, 85.9% of patients were identified as “Freezers” using FOG‐Q item 3 (≥1) and 44.1% using UPDRS item 14 (≥1) (P < 0.001). FOG‐Q was a reliable tool for the assessment of treatment intervention. FOG‐Q item 3 was effective as a screening question for the presence of FOG. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21745
Affiliations:
- Allemagne, Autriche, Espagne, France, Israël, Italie, Royaume-Uni
- Angleterre, Catalogne, District de Giessen, Grand Londres, Hesse (Land), Latium, Midi-Pyrénées, Tyrol (Land)
- Barcelone, Innsbruck, Londres, Marbourg, Rome, Toulouse
- Université Toulouse III - Paul Sabatier, Université de Toulouse, Université de médecine d'Innsbruck
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000F07
- to stream Istex, to step Curation: 000F07
- to stream Istex, to step Checkpoint: 000B95
- to stream PubMed, to step Corpus: 001E78
- to stream PubMed, to step Curation: 001E78
- to stream PubMed, to step Checkpoint: 001B07
- to stream Ncbi, to step Merge: 002486
- to stream Ncbi, to step Curation: 002486
- to stream Ncbi, to step Checkpoint: 002486
- to stream Main, to step Merge: 002854
- to stream PascalFrancis, to step Corpus: 000F22
- to stream PascalFrancis, to step Curation: 001D97
- to stream PascalFrancis, to step Checkpoint: 000C65
- to stream Main, to step Merge: 002D62
- to stream Main, to step Curation: 001F93
- to stream Main, to step Exploration: 001F93
- to stream France, to step Extraction: 000231
Links to Exploration step
ISTEX:1E8B00D3E2E11843140BEB664E928F790D6A6A7DLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Validation of the freezing of gait questionnaire in patients with Parkinson's disease</title><author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name></author><author><name sortKey="Tal, Joseph" sort="Tal, Joseph" uniqKey="Tal J" first="Joseph" last="Tal">Joseph Tal</name></author><author><name sortKey="Azulay, Tali" sort="Azulay, Tali" uniqKey="Azulay T" first="Tali" last="Azulay">Tali Azulay</name></author><author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Olivier Rascol</name><affiliation><country>France</country><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name></author><author><name sortKey="Oertel, Wolfgang" sort="Oertel, Wolfgang" uniqKey="Oertel W" first="Wolfgang" last="Oertel">Wolfgang Oertel</name></author><author><name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner Poewe</name><affiliation><country>Autriche</country><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1E8B00D3E2E11843140BEB664E928F790D6A6A7D</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1002/mds.21745</idno><idno type="url">https://api.istex.fr/document/1E8B00D3E2E11843140BEB664E928F790D6A6A7D/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000F07</idno><idno type="wicri:Area/Istex/Curation">000F07</idno><idno type="wicri:Area/Istex/Checkpoint">000B95</idno><idno type="wicri:doubleKey">0885-3185:2009:Giladi N:validation:of:the</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:19127595</idno><idno type="wicri:Area/PubMed/Corpus">001E78</idno><idno type="wicri:Area/PubMed/Curation">001E78</idno><idno type="wicri:Area/PubMed/Checkpoint">001B07</idno><idno type="wicri:Area/Ncbi/Merge">002486</idno><idno type="wicri:Area/Ncbi/Curation">002486</idno><idno type="wicri:Area/Ncbi/Checkpoint">002486</idno><idno type="wicri:Area/Main/Merge">002854</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:09-0218140</idno><idno type="wicri:Area/PascalFrancis/Corpus">000F22</idno><idno type="wicri:Area/PascalFrancis/Curation">001D97</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000C65</idno><idno type="wicri:doubleKey">0885-3185:2009:Giladi N:validation:of:the</idno><idno type="wicri:Area/Main/Merge">002D62</idno><idno type="wicri:Area/Main/Curation">001F93</idno><idno type="wicri:Area/Main/Exploration">001F93</idno><idno type="wicri:Area/France/Extraction">000231</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Validation of the freezing of gait questionnaire in patients with Parkinson's disease</title><author><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Movement Disorders Unit, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel‐Aviv University, Tel‐Aviv</wicri:regionArea><wicri:noRegion>Tel‐Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Tal, Joseph" sort="Tal, Joseph" uniqKey="Tal J" first="Joseph" last="Tal">Joseph Tal</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>TechnoStat Ltd, Hod Hasharon</wicri:regionArea><wicri:noRegion>Hod Hasharon</wicri:noRegion></affiliation></author><author><name sortKey="Azulay, Tali" sort="Azulay, Tali" uniqKey="Azulay T" first="Tali" last="Azulay">Tali Azulay</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>TechnoStat Ltd, Hod Hasharon</wicri:regionArea><wicri:noRegion>Hod Hasharon</wicri:noRegion></affiliation></author><author><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Pharmacologie Medicale et Clinique, Faculté de Médecine, Toulouse Cedex</wicri:regionArea><wicri:noRegion>Toulouse Cedex</wicri:noRegion><wicri:noRegion>Toulouse Cedex</wicri:noRegion><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Rabin Medical Centre, Sackler School of Medicine, Tel‐Aviv University, Tel‐Aviv</wicri:regionArea><wicri:noRegion>Tel‐Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Oertel, Wolfgang" sort="Oertel, Wolfgang" uniqKey="Oertel W" first="Wolfgang" last="Oertel">Wolfgang Oertel</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Centre of Nervous Diseases, Philipps‐University of Marburg, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University of Innsbruck, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neuroscience and Neuromed, University La Sapienza, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Neurology Department, Hospital Clinic, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2009-04-15">2009-04-15</date><biblScope unit="vol">24</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="655">655</biblScope><biblScope unit="page" to="661">661</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1E8B00D3E2E11843140BEB664E928F790D6A6A7D</idno><idno type="DOI">10.1002/mds.21745</idno><idno type="ArticleID">MDS21745</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Analysis of Variance</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Catechols (therapeutic use)</term><term>Double-Blind Method</term><term>Female</term><term>Freezing</term><term>Freezing Reaction, Cataleptic (drug effects)</term><term>Freezing Reaction, Cataleptic (physiology)</term><term>Gait Disorders, Neurologic (chemically induced)</term><term>Gait Disorders, Neurologic (diagnosis)</term><term>Gait Disorders, Neurologic (drug therapy)</term><term>Gait Disorders, Neurologic (physiopathology)</term><term>Human</term><term>Humans</term><term>Indans (therapeutic use)</term><term>Levodopa (adverse effects)</term><term>Male</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Neuroprotective Agents (therapeutic use)</term><term>Nitriles (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Principal Component Analysis</term><term>Psychiatric Status Rating Scales</term><term>Questionnaire</term><term>Questionnaires</term><term>Rasagiline</term><term>Reproducibility of Results</term><term>Severity of Illness Index</term><term>Statistics as Topic</term><term>Validation</term><term>freezing of gait</term><term>rasagiline</term><term>validation</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Catechols</term><term>Indans</term><term>Neuroprotective Agents</term><term>Nitriles</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Gait Disorders, Neurologic</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Gait Disorders, Neurologic</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Freezing Reaction, Cataleptic</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Gait Disorders, Neurologic</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Freezing Reaction, Cataleptic</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Gait Disorders, Neurologic</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Analysis of Variance</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Principal Component Analysis</term><term>Psychiatric Status Rating Scales</term><term>Questionnaires</term><term>Reproducibility of Results</term><term>Severity of Illness Index</term><term>Statistics as Topic</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Congélation</term><term>Homme</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term><term>Questionnaire</term><term>Rasagiline</term><term>Validation</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Congélation</term><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To revalidate the Freezing of Gait Questionnaire (FOG‐Q), patients with Parkinson's disease (PD) were randomly assigned to receive rasagiline (1 mg/day) (n = 150), entacapone (200 mg with each dose of levodopa) (n = 150), or placebo (n = 154). Patients were assessed at baseline and after 10 weeks using the FOG‐Q, Unified Parkinson's Disease Rating Scale (UPDRS), Beck Depression Inventory (BDI), and Parkinson's Disease Questionnaire (PDQ‐39). FOG‐Q dimensionality, test–retest reliability, and internal reliability were examined. Convergent and divergent validities were assessed by correlating FOG‐Q with UPDRS, BDI, and PDQ‐39. Comparisons between FOG‐Q item 3 and UPDRS item 14 were also made. Principal component analysis indicated that FOG‐Q measures a single dimension. Test–retest reliability and internal reliability of FOG‐Q score was high. FOG‐Q was best correlated to items of the UPDRS relating to walking, general motor issues, and mobility. Correlations between baseline and endpoint suggested that FOG‐Q item 3 is at least as reliable as UPDRS item 14. At baseline, 85.9% of patients were identified as “Freezers” using FOG‐Q item 3 (≥1) and 44.1% using UPDRS item 14 (≥1) (P < 0.001). FOG‐Q was a reliable tool for the assessment of treatment intervention. FOG‐Q item 3 was effective as a screening question for the presence of FOG. © 2007 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Autriche</li><li>Espagne</li><li>France</li><li>Israël</li><li>Italie</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Catalogne</li><li>District de Giessen</li><li>Grand Londres</li><li>Hesse (Land)</li><li>Latium</li><li>Midi-Pyrénées</li><li>Tyrol (Land)</li></region><settlement><li>Barcelone</li><li>Innsbruck</li><li>Londres</li><li>Marbourg</li><li>Rome</li><li>Toulouse</li></settlement><orgName><li>Université Toulouse III - Paul Sabatier</li><li>Université de Toulouse</li><li>Université de médecine d'Innsbruck</li></orgName></list><tree><country name="Israël"><noRegion><name sortKey="Giladi, Nir" sort="Giladi, Nir" uniqKey="Giladi N" first="Nir" last="Giladi">Nir Giladi</name></noRegion><name sortKey="Azulay, Tali" sort="Azulay, Tali" uniqKey="Azulay T" first="Tali" last="Azulay">Tali Azulay</name><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name><name sortKey="Tal, Joseph" sort="Tal, Joseph" uniqKey="Tal J" first="Joseph" last="Tal">Joseph Tal</name></country><country name="France"><region name="Midi-Pyrénées"><name sortKey="Rascol, Oliver" sort="Rascol, Oliver" uniqKey="Rascol O" first="Oliver" last="Rascol">Olivier Rascol</name></region></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name></region></country><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Oertel, Wolfgang" sort="Oertel, Wolfgang" uniqKey="Oertel W" first="Wolfgang" last="Oertel">Wolfgang Oertel</name></region></country><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner Poewe</name></region></country><country name="Italie"><region name="Latium"><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name></region></country><country name="Espagne"><region name="Catalogne"><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000231 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000231 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:1E8B00D3E2E11843140BEB664E928F790D6A6A7D
|texte= Validation of the freezing of gait questionnaire in patients with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |